Moreover, the same compound had additional preclinical activity in certain BRAF non-V600 NSCLC models [137], indicating that a RAF inhibitor with distinct biochemical characteristics can provide additional benefits. This evidence concerns the gene RAF1 and non-small cell lung carcinoma.